Celularity Inc., a leader in cellular and regenerative medicine, has announced a strategic collaboration with BlueSphere Bio, Inc., focused on advancing the manufacturing of BSB’s innovative T cell receptor therapies. This agreement underscores Celularity’s expertise and capabilities in large-scale, cGMP-compliant manufacturing, positioning the company as a key player in the cell therapy sector.
The collaboration will specifically target the production of BSB’s TCR-based therapies for treating high-risk leukemias, including Acute Myelogenous Leukemia. Celularity will leverage its state-of-the-art manufacturing facility in Florham Park, New Jersey, to handle all aspects of cell therapy production. This includes the critical areas of Chemistry, Manufacturing, and Controls (CMC), as well as Quality Assurance and Quality Control. Celularity’s 37,000-square-foot facility will house the dedicated staff and resources for this initiative, ensuring the production of high-quality therapeutic products both domestically and internationally.
“This collaboration is an important step in advancing the treatment of high-risk leukemias,” said Dr. Robert J. Hariri, CEO and Chairman of Celularity. “It also highlights our ability to support not only our own clinical programs but to create a collaborative platform for other companies, like BlueSphere, that require flexible and reliable manufacturing solutions.”
Also Read: MGI Tech Partners with Oncoclínicas&Co to Advance Genomic Innovation in Oncology
BlueSphere Bio’s CEO, Keir Loiacono, also emphasized the value of the partnership, noting, “Reliable and flexible manufacturing are critical to a successful cell therapy program. The quality of Celularity’s business model and facility will provide BlueSphere with the necessary tools to advance our assets to the clinic in an affordable fashion, without relinquishing control over our processes.”
This collaboration marks a significant milestone for Celularity, demonstrating its growing role in supporting the development of cutting-edge cell therapies and expanding its business model to include high-value manufacturing partnerships.